Genetic Technologies EBIT

Genetic Technologies (GENE) currently reports a EBIT of $-19M as of June 2024. That compares with $-15M in the prior-year period — down 30.0% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Genetic Technologies's EBIT history and peer comparisons.

Genetic Technologies's EBIT decreased from $-15M to $-19M — a 30.0% year-over-year decrease (period ending June 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Genetic Technologies's EBIT of $-19M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Genetic Technologies reported $-19M in EBIT as of June 2024. That compares with $-15M in the prior-year period — down 30.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-19M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Genetic Technologies, and consider following GENE for alerts when major investors trade the stock.